Why Is Tango Therapeutics (TNGX) Down 6.2% Since Last Earnings Report?

TNGX fell 6.2% since reporting Q2 2026 earnings, trailing the S&P 500 as the company posted a loss of 37 cents per share that missed consensus estimates. The wider-than-expected loss stemmed from ballooning operating expenses: R&D costs climbed 13% while general and administrative expenses nearly doubled year-over-year. Collaboration revenue dropped to zero from $3.2 million in the prior-year quarter following the end of TNGX's partnership with Gilead.

Analyst sentiment has deteriorated in the wake of the report. Consensus estimates have been revised downward by 10.16% over the past month, according to Zacks Investment Research. The firm rates TNGX at Rank #3 (Hold), and the stock scores poorly across value, growth, and momentum metrics in Zacks' VGM screening system.

The revenue wipeout from the Gilead partnership conclusion removes a near-term cash source, while the doubling of G&A expenses raises questions about operational efficiency as the company advances its pipeline.